Article
Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.
Molecular diagnosis & therapy - 1 Aug 2014
Dudley Jonathan C, Gurda Grzegorz T, Tseng Li-Hui, Anderson Derek A, Chen Guoli, Taube Janis M, Gocke Christopher D, Eshleman James R, Lin Ming-Tseh
Abstract excerpt
BACKGROUND: Detection of BRAF mutations is an established standard of care to predict small-molecule inhibitor (vemurafenib) response in metastatic melanoma. Molecular assays should be designed to detect not only the most common p.V600E mutation, but also p.V600K and other non-p.V600E mutations. OBJECTIVE: The purpose of this study was to assess if tumor cellularity can function as a quality assurance (QA)...
Topics
- DNA Mutational Analysis
- Humans
- Melanoma
- Mutation
- Proto-Oncogene Proteins B-raf
- Skin Neoplasms